HAART in pregnant HIV-infected women.: Efficacy and safety for the mothers and infants

被引：0

作者：

Vandercam, B ^{[1
]}

Abarzúa, F ^{[1
]}

Dupont, M ^{[1
]}

VanWijngaerden, E ^{[1
]}

Hubinont, C ^{[1
]}

Bernard, P ^{[1
]}

Brichard, B ^{[1
]}

机构：

[1] St Luc Univ Hosp, Dept Obstet, Brussels, Belgium

来源：

XV INTERNATIONAL AIDS CONFERENCE: CLINICAL RESEARCH, TREATMENT, AND CARE | 2004年

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The use of antiretroviral therapy has reduced mother-to-child trans mission (MCT) of HIV. However, this benefit is associated with the risk of in utero and neonatal drug exposure. Fifty-six pregnant women receiving HAART were included in an observational study from Jan 1999 to Jan 2.004. There was no difference in prematurity rates by type or timing of antiretroviral therapy. One case of neonatal death (720 gr) was observed (HELLP syndrome). No case of MCT of HIV was observed, the viral load being undetectable at delivery (< 250 copies/ml) in 96.4% of cases. None of the children was breastfed. Most frequent complications for children were reversible anemia but the presence of serious infections (3) and infant deaths (3) argue for long-term follow up.

引用

页码：121 / 125

页数：5